Longboard Pharmaceuticals (Nasdaq:LBPH) - Hisse Senedi Fiyatı, Haberler ve Analizler

LBPH Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Longboard Pharmaceuticals, Inc. nörolojik hastalıklar için yeni ve dönüştürücü ilaçlar geliştirmeye odaklanmaktadır. Daha fazla detay

LBPH temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 7.6% oranında düşmesi öngörülüyor

+ 1 daha fazla risk

Longboard Pharmaceuticals, Inc. Rakipler

Ligand Pharmaceuticals

NasdaqGM:LGND

US$2.3b

Wave Life Sciences

NasdaqGM:WVE

US$2.2b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.1b

Belite Bio

NasdaqCM:BLTE

US$2.3b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Longboard Pharmaceuticals
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$59.91
52 Haftanın En Yüksek Seviyesi	US$59.95
52 Haftanın En Düşük Seviyesi	US$3.60
Beta	1.09
11 Aylık Değişim	0.52%
3 Aylık Değişim	70.20%
1 Yıllık Değişim	1,405.28%
33 Yıllık Değişim	954.75%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	259.82%

Son Haberler & Güncellemeler

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Hissedar Getirileri

	LBPH	US Pharmaceuticals	US Pazar
7D	0.3%	2.8%	2.2%
1Y	1,405.3%	11.8%	32.6%

Getiri vs. Endüstri: LBPH geçen yıl % 11.8 oranında getiri sağlayan US Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: LBPH geçen yıl % 32.6 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is LBPH's price volatile compared to industry and market?
LBPH volatility
LBPH Average Weekly Movement	16.9%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: LBPH hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: LBPH 'nin haftalık oynaklığı son bir yılda 46% dan 17% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2020	50	Kevin Lind	www.longboardpharma.com

Klinik aşamada bir biyofarmasötik şirketi olan Longboard Pharmaceuticals, Inc. nörolojik hastalıklar için yeni ve dönüştürücü ilaçlar geliştirmeye odaklanmaktadır. Şirket, gelişimsel ve epileptik ensefalopatilerle ilişkili nöbetlerin tedavisi için Faz 1b/2a klinik çalışmasını tamamlamış olan bexicaserin'i (LP352) geliştirmektedir. Ayrıca nörolojik hastalıkların tedavisi için bir S1P reseptör modülatörü olan LP659'u geliştirmektedir.

Longboard Pharmaceuticals, Inc. Temel Bilgiler Özeti

Longboard Pharmaceuticals'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
LBPH temel i̇stati̇sti̇kler
Piyasa değeri	US$2.33b
Kazançlar(TTM)	-US$76.34m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-30.6x

F/K Oranı

LBPH aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
LBPH gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$76.34m
Kazançlar	-US$76.34m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.96
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

LBPH uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

LBPH Stoklara Genel Bakış

Risk Analizi

Longboard Pharmaceuticals, Inc. Rakipler

NasdaqGM:LGND

US$2.3b

NasdaqGM:WVE

US$2.2b

NasdaqGS:AMPH

US$2.1b

NasdaqCM:BLTE

US$2.3b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Longboard Pharmaceuticals, Inc. Temel Bilgiler Özeti

0.0x

-30.6x

Kazanç ve Gelir